Racial Disparities in Lung Cancer: Part 3 of a Special Series
In part 3 of this series, we interviewed Samuel Cykert, MD, who helped build a system-based intervention to reduce racial gaps and improve care for all patients with lung cancer.
In part 3 of this series, we interviewed Samuel Cykert, MD, who helped build a system-based intervention to reduce racial gaps and improve care for all patients with lung cancer.
In part 2 of this 3-part series, the recent State of Lung Cancer report by the American Lung Association, which included state-level and national-level data on lung cancer in people of color for the first time.
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
COVID-19 has caused significant disruption in lung cancer screening.
A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
Less than 1 percent of patients receiving antitumor treatment between Jan. 15 and May 4, 2020, developed COVID-19
The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.
Lower alpha diversity of the oral microbiota is associated with an increased risk for lung cancer in never-smokers, and the abundance of specific taxa are associated with altered risk.